Corpus ID: 23184840

Development of new antiallergic drugs (cromolyn sodium, lodoxamide tromethamine). What is the role of cholinergic stimulation in the biphasic dose response?

  title={Development of new antiallergic drugs (cromolyn sodium, lodoxamide tromethamine). What is the role of cholinergic stimulation in the biphasic dose response?},
  author={H. Johnson and G. J. White},
  journal={Monographs in allergy},
The antiallergy drugs, cromolyn sodium and lodoxamide tromethamine (U-42,585E) show in vitro dose responses which are bell-shaped or biphasic in mast cells. The nature of the biphasic dose response is poorly understood; however, through the use of specific antagonists, it has been possible to show that at the high concentrations of these drugs leading to enhanced histamine release or multiple high-dose tachyphylaxis, a cholinergic receptor is stimulated in the cell. This receptor is muscarinic… Expand
The characterization of lodoxamide, a very active inhibitor of mediator release, in animal and human models of asthma
Rat and primate models not being predictive for human long-term clinical asthma in the characterization of anti-release compounds is not known. Expand
Changes induced by sodium cromoglycate on brain serotonin turnover in morphine dependent and abstinent mice
Previous administration of CRO prior to naloxone challenge induced a significant increase in the 5HIAA/5HT ratio in the hypothalamus and striatum, which is discussed as the reason for the preventive effect ofCRO on jumping behaviour in morphine abstinent mice. Expand
Ocular Allergy Guidelines
Advances in the basic understanding of these conditions are providing the foundation for guidelines that improve the ocular health of patients with ocular allergies, and for interventional therapeutic strategies and symptomatic relief. Expand
Update on ocular allergy treatment
  • L. Bielory
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2002
The increased interest in advancing ocular treatment will lead to the development of additional therapies, novel pharmacokinetic delivery systems and, thus, improved healthcare outcomes for patients with allergic conjunctivitis. Expand
Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders.
Ocular allergy is underdiagnosed and has a significant impact on the life of the patient, and it is vital to reach a better understanding of ocular allergic mechanisms and inflammation, which may lead to improved treatment. Expand